Respiratory Syncytial Virus: Babies
(asked on 13th January 2016) - View Source
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, if he will assess the effect of individual funding requests for palivizumab on premature babies at risk of severe complications from respiratory syncytial virus.
This question was answered on 22nd January 2016
NHS England has advised that it is monitoring the level of individual funding requests for patients who do not meet the criteria for palivizumab. NHS England aims to finalise an analysis of this data in April 2016 and will report its findings to the neonatal care clinical reference group.